We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZYTORVI Dr Reddys Laboratories Australia Pty Ltd
Product name
ZYTORVI
Accepted date
Sep-2025
Active ingredients
toripalimab
Proposed indication
ZYTORVI (toripalimab) is proposed for the first-line treatment of oesophageal squamous cell carcinoma (OSCC) together with two other anticancer medicines, cisplatin and paclitaxel. It is for OSCC that cannot be removed by surgery, has come back, or has spread to other parts of the body.
Application type
C (new indication)
Publication date
Sep-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.